Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy: A systematic review

被引:74
|
作者
Cruz, Dinna N.
Perazella, Mark A.
Bellomo, Rinaldo
Corradi, Valentina
de Cal, Massimo
Kuang, Dingwei
Ocampo, Catalina
Nalesso, Federico
Ronco, Claudio
机构
[1] San Bortolo Hosp, Dept Nephrol, I-36100 Vicenza, Italy
[2] Yale Univ, Sch Med, Dept Med, Nephrol Sect, New Haven, CT 06510 USA
[3] Austin & Rapatriat Med Ctr, Dept Intens Care, Melbourne, Vic, Australia
[4] Austin & Rapatriat Med Ctr, Dept Med, Melbourne, Vic, Australia
关键词
continuous renal replacement therapy; hemodialysis (HD); hemofiltration; meta-analysis; prevention; radiocontrast nephropathy;
D O I
10.1053/j.ajkd.2006.05.023
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background Radiocontrast-induced nephropathy (RCIN) causes acute kidney injury and increases mortality. Studies have examined the capacity of various forms of extracorporeal blood purification therapies for the prevention of RCIN, with conflicting results. We conducted a systematic review of published trials to determine whether periprocedural extracorporeal blood purification prevents RCIN. Methods: We searched PubMed, the Cochrane Collaboration Database, EMBASE, and CINAHL through January 2006 and bibliographies of retrieved articles and consulted with experts to identify relevant studies. Published studies of extracorporeal blood purification for the prevention of RCIN in patients receiving radiocontrast were included. Two authors reviewed all citations. The primary end point is the incidence of RCIN, defined as an increase in serum creatinine concentration (>= 0.5 mg/dL [>= 44 mu mol/L]). Results were combined on the risk ratio scale. Random-effects models were used. Sensitivity analyses were performed to evaluate the effects of extracorporeal blood purification modality, study design, and sample size. Results: Eight trials (6 randomized controlled trials, 2 nonrandomized trials) were included in the analysis (pooled sample size, 412). Six trials assessed hemodialysis, whereas 1 trial each assessed continuous venovenous hemofiltration and continuous venovenous hemodiafiltration. The incidence of RCIN was 35.2% in the standard-medical-therapy group and 27.8% in the extracorporeal-blood-purification group. Extracorporeal blood purification did not decrease the incidence of RCIN significantly compared with standard medical therapy (risk ratio, 0.97; 95% confidence interval, 0.44 to 2.14); however, intertrial heterogeneity was high. Limiting analysis to only randomized trials did not eliminate heterogeneity, but limiting analysis to only hemodialysis trials did. Periprocedural hemodialysis did not decrease the incidence of RCIN. Conclusion: This critical analysis of the published literature suggests that periprocedural extracorporeal blood purification does not decrease the incidence of RCIN compared with standard medical therapy.
引用
收藏
页码:361 / 371
页数:11
相关论文
共 50 条
  • [21] Efficacy of nicardipine in radiocontrast-induced nephropathy (RCIN).
    Rab, S
    Thakur, V
    JOURNAL OF INVESTIGATIVE MEDICINE, 1999, 47 (02) : 121A - 121A
  • [22] Radiocontrast-induced nephropathy and percutaneous coronary intervention: a review of preventive measures
    Mintz, EP
    Gruberg, L
    EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (05) : 639 - 652
  • [23] The value of N-acetylcysteine in the prevention of radiocontrast-induced nephropathy appears questionable
    Hoffmann, U
    Fischereder, M
    Kruger, B
    Drobnik, W
    Kramer, BK
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 280A - 280A
  • [24] Effects of agmatine against radiocontrast-induced nephropathy in rabbit
    Sugiura, Takahiro
    Ohshiha, Yasuhiro
    Matsui, Eiji
    Imaizumi, Takahiro
    Kawasaki, Yukiko
    Toyoshi, Tohru
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2016, 130 (03) : S204 - S204
  • [25] Novel biomarker analysis in radiocontrast-induced nephropathy rats
    Sugiura, Takahiro
    Hirasawa, Yasushi
    Iwata, Koji
    Imaizumi, Takahito
    Kawasaki, Yukiko
    Toyoshi, Tohru
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2014, 124 : 226P - 226P
  • [26] Evaluation of types of protection against radiocontrast-induced nephropathy
    Ursu, Michaela
    Ferentinou, Eleftheria
    Ziakka, Stavroula
    Kaperonis, Nikolaos
    Karabinis, Ioannis
    Biblaki, Dimitra
    Ntatsis, George
    Papagalanis, Nikolaos
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 : 111 - 111
  • [27] Silymarin protects against radiocontrast-induced nephropathy in mice
    Santos, Veronica de Souza
    Peters, Beatriz
    Coco, Larissa Zambom
    Alves, Gisele Maziero
    Evangelista Monteiro de Assis, Aricia Leone
    Nogueira, Breno Valentim
    Meyrelles, Silvana Santos
    Porto, Marcella Leite
    Vasquez, Elisardo Corral
    Campagnaro, Bianca Prandi
    Costa Pereira, Thiago Melo
    LIFE SCIENCES, 2019, 228 : 305 - 315
  • [28] Reactive Oxygen Species and the Pathogenesis of Radiocontrast-Induced Nephropathy
    Heyman, Samuel N.
    Rosen, Seymour
    Khamaisi, Mogher
    Idee, Jean-Marc
    Rosenberger, Christian
    INVESTIGATIVE RADIOLOGY, 2010, 45 (04) : 188 - 195
  • [29] Low incidence of radiocontrast-induced nephropathy in a surgical ICU
    Haveman, JW
    Nijsten, MWN
    INTENSIVE CARE MEDICINE, 2002, 28 : S185 - S185
  • [30] RADIOCONTRAST-INDUCED NEPHROPATHY IN HUMANS - ROLE OF RENAL VASOCONSTRICTION
    WEISBERG, LS
    KURNIK, PB
    KURNIK, BRC
    KIDNEY INTERNATIONAL, 1992, 41 (05) : 1408 - 1415